STOCK TITAN

Inozyme Pharma, Inc. - INZY STOCK NEWS

Welcome to our dedicated page for Inozyme Pharma news (Ticker: INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.

Overview of Inozyme Pharma, Inc.

Inozyme Pharma, Inc. (INZY) is a clinical-stage biopharmaceutical company dedicated to developing novel enzyme replacement therapies for rare diseases. Specializing in disorders of paradoxical mineralization and intimal proliferation, the company targets severe metabolic conditions that affect bone health, vascular function, and soft tissue integrity. Its innovative approach centers on the modulation of the PPi-Adenosine pathway, a critical biochemical mechanism involved in preventing pathologic calcification and abnormal vascular smooth muscle proliferation.

Core Therapeutic Focus

At the heart of Inozyme Pharma is its commitment to addressing disorders such as ENPP1 Deficiency and ABCC6 Deficiency, both of which lead to devastating clinical manifestations including arterial calcification and musculoskeletal complications. The company is also actively investigating applications in calciphylaxis, a rare and life-threatening complication associated with end-stage kidney disease. By harnessing its expertise in enzyme replacement therapy, Inozyme aims to offer a transformative treatment option where no approved therapies currently exist.

Innovative Technology and Product Candidate

The company’s lead candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein designed to correct deficiencies in the PPi-Adenosine pathway. INZ-701 works by metabolizing extracellular ATP to generate inorganic pyrophosphate (PPi), a natural inhibitor of pathological mineralization, and by producing adenosine, which plays a role in regulating intimal proliferation. This dual mechanism offers significant potential to mitigate the underlying causes of critical rare diseases that affect bone, vascular, and soft tissue function.

Research, Development, and Clinical Strategy

Inozyme Pharma is committed to a robust clinical development program, conducting early-phase trials to evaluate the safety, tolerability, as well as the pharmacokinetic and pharmacodynamic profiles of INZ-701. The company’s research strategy is underpinned by in-depth natural history studies and retrospective analyses, which have enhanced understanding of these rare conditions and refined clinical trial design. By leveraging advanced biotechnological techniques alongside strategic clinical collaborations, Inozyme Pharma is positioned to deliver meaningful insights into disease mechanisms and potential therapeutic benefits.

Scientific Expertise and Market Position

With a strong foundation in molecular biology and genetic engineering, Inozyme Pharma demonstrates expertise in the design and development of enzyme replacement therapies. The company is recognized for its scientific rigor and methodical approach to drug development, which is reflected in its comprehensive evaluation of the PPi-Adenosine pathway. This focus not only supports its lead candidate but also positions Inozyme as a key player in the increasingly competitive rare disease therapeutic landscape. The firm’s activities, including multiple clinical studies, strategic research partnerships, and participation in scientific forums, underscore its commitment to advancing treatments for debilitating metabolic disorders.

Therapeutic Impact and Unmet Need

Rare diseases such as ENPP1 Deficiency and ABCC6 Deficiency present high unmet medical needs due to their severe impact on patient quality of life, including significant skeletal, cardiovascular, and neurological challenges. In addressing these conditions, Inozyme Pharma’s work is not only scientifically innovative but also critically important in the broader context of rare disease management. Its therapeutic candidate, INZ-701, offers a novel mechanism of action that could potentially alter the course of these diseases by restoring a key regulatory pathway, thereby reducing morbidity and improving patient outcomes.

Conclusion

Inozyme Pharma, Inc. combines advanced biotechnological innovation with deep expertise in rare disease pathology to address some of the most challenging conditions in modern medicine. Through its targeted approach to enzyme replacement therapy and its focus on the PPi-Adenosine pathway, the company continues to push the boundaries of therapeutic discovery in the rare disease field. This comprehensive strategy leverages both scientific insight and clinical precision to potentially transform treatment paradigms for patients suffering from debilitating disorders affecting bone health and vascular integrity.

Rhea-AI Summary

Inozyme Pharma announced the acceptance of its Clinical Trial Application (CTA) for INZ-701 to begin a Phase 1/2 trial targeting ABCC6 Deficiency. This milestone is part of the ANSM's Fast Track procedure. ABCC6 Deficiency is a rare, inherited disorder leading to severe calcification, affecting over 67,000 people globally. INZ-701 aims to restore plasma pyrophosphate (PPi) levels, crucial for preventing harmful calcification. The trial is set to start in mid-2021, with preliminary safety data expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary

Inozyme Pharma reported Q1 2021 financial results, highlighting a net loss of $11.1 million, or $0.47 per share. The company maintains a solid cash position with $147.6 million, expected to support operations until Q4 2022. Inozyme filed a Clinical Trial Application for INZ-701 targeting ABCC6 Deficiency, aiming to start a Phase 1/2 trial in mid-2021. Recently published preclinical data in the Journal of Bone and Mineral Research showcases INZ-701’s potential for treating ENPP1 Deficiency. The company presented findings from a Burden of Illness Study, marking significant progression in its clinical development strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Summary

Inozyme Pharma presented preclinical data at the European Calcified Tissue Society Congress, indicating that INZ-701, an enzyme replacement therapy, successfully increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency.

This is significant as ABCC6 Deficiency, associated with Pseudoxanthoma Elasticum (PXE), currently has no approved treatments. Results showed a 68% to 74% reduction in calcification, highlighting INZ-701’s potential to address this rare disease affecting over 67,000 individuals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Summary

Inozyme Pharma, a biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13 at 11:45 a.m. ET. The event will be available via live webcast on Inozyme’s website, with a replay accessible for 90 days post-event. Inozyme develops innovative therapeutics targeting diseases caused by abnormal mineralization, specifically focusing on ENPP1 and ABCC6 Deficiencies. The company aims to address the underlying causes of these rare genetic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
-
Rhea-AI Summary

Inozyme Pharma announced promising preclinical results for its lead candidate, INZ-701, in treating ENPP1 Deficiency. Peer-reviewed findings in the Journal of Bone and Mineral Research revealed that INZ-701 increased plasma levels of pyrophosphate (PPi), improved several disease markers, and reduced mortality in ENPP1-deficient mice. Key results include a dose-dependent increase in PPi levels and prevention of ectopic calcification. Inozyme plans to initiate Phase 1/2 clinical trials for ENPP1 Deficiency in mid-2021, strengthening INZ-701's potential as a therapeutic option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY) announced the presentation of preclinical data on INZ-701, targeting ABCC6 Deficiency/Pseudoxanthoma elasticum (PXE), at two upcoming conferences. The first, at the Society for Investigative Dermatology 2021 Virtual Meeting on May 5, focuses on preventing ectopic mineralization in a mouse model. The second presentation is at the European Calcified Tissue Society 2021 Digital Congress on May 7, highlighting INZ-701's efficacy as a recombinant ENPP1-Fc protein. The company is developing therapeutics for rare diseases related to abnormal mineralization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
conferences clinical trial
Rhea-AI Summary

Inozyme Pharma presented new data revealing the significant disease burden of ENPP1 and ABCC6 Deficiencies at the ACMG annual meeting. The study showcased how these rare genetic diseases impact patients differently across age groups, highlighting severe symptoms such as cardiac issues and skeletal abnormalities. The research included responses from 38 patients across nine countries, emphasizing the need for improved diagnosis and management strategies. Inozyme is preparing to start Phase 1/2 trials for its therapy INZ-701 targeting these disorders in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY) announced the presentation of a study on the burden of illness associated with infantile onset ABCC6 and ENPP1 deficiency at the ACMG Annual Clinical Genetics Meeting from April 13-16, 2021. The poster titled 'From the Voice of Patients and Caregivers: Burden of Illness in Infantile Onset ABCC6 and ENPP1 Deficiency' will be displayed starting April 14, 2021. The research focuses on these rare diseases affecting mineralization pathways. The results will be available on Inozyme’s website post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
conferences
-
Rhea-AI Summary

Inozyme Pharma has announced changes to its Scientific Advisory Board (SAB), welcoming three experts in vascular calcification and renal disease: W Charles O’Neill IV, Jouni Uitto, and Paul B. Yu. David Thompson, former Chief Scientific Officer, joins the SAB as well. The transition follows the departure of three members, aiming to strengthen the company's focus on rare diseases linked to mineralization abnormalities. The new appointees bring valuable expertise that will aid Inozyme in its research and development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
management
Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY) received Orphan Drug Designation from the FDA for INZ-701, targeting ABCC6 deficiency. The company plans to initiate Phase 1/2 trials for both ENPP1 and ABCC6 deficiencies in 2021. As of December 31, 2020, cash reserves stood at $159.9 million, projected to fund operations into the second half of 2022. R&D expenses increased significantly to $46.5 million, driven by asset acquisitions and clinical preparations. The net loss reported was $56.4 million, translating to a loss of $5.11 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags

FAQ

What is the current stock price of Inozyme Pharma (INZY)?

The current stock price of Inozyme Pharma (INZY) is $0.87 as of April 1, 2025.

What is the market cap of Inozyme Pharma (INZY)?

The market cap of Inozyme Pharma (INZY) is approximately 55.4M.

What is the core focus of Inozyme Pharma, Inc.?

Inozyme Pharma is focused on developing novel enzyme replacement therapies for rare diseases, particularly those affecting bone health, vascular function, and soft tissues through targeting the PPi-Adenosine pathway.

Which conditions are primarily targeted by the company?

The company primarily targets conditions such as ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis, which are characterized by pathologic mineralization and abnormal vascular smooth muscle proliferation.

What is INZ-701?

INZ-701 is a recombinant, genetically engineered fusion protein that functions as an enzyme replacement therapy aimed at restoring the balance in the PPi-Adenosine pathway to counteract disorders of mineralization and intimal proliferation.

How does INZ-701 work in the body?

INZ-701 metabolizes extracellular ATP to generate inorganic pyrophosphate (PPi), which inhibits abnormal mineralization, and produces adenosine, which helps regulate vascular smooth muscle proliferation.

What stage of development is Inozyme Pharma currently in?

Inozyme Pharma is a clinical-stage biopharmaceutical company actively conducting early-phase trials and natural history studies to evaluate the safety and efficacy of its therapeutic candidates.

Why is the PPi-Adenosine pathway significant?

The PPi-Adenosine pathway plays a crucial role in regulating mineralization and vascular smooth muscle proliferation. Disruptions in this pathway can lead to severe conditions such as ENPP1 and ABCC6 Deficiencies, making it a key target for therapeutic intervention.

How does Inozyme Pharma differentiate itself from its competitors?

The company differentiates itself through its specialized focus on the PPi-Adenosine pathway and the development of targeted enzyme replacement therapies, supported by deep scientific expertise and comprehensive clinical research.

What is the potential impact of Inozyme Pharma's research?

By addressing the underlying molecular mechanisms of rare metabolic disorders, Inozyme Pharma's research has the potential to significantly improve clinical outcomes and quality of life for patients suffering from debilitating conditions with limited treatment options.

Are there any approved therapies for the targeted diseases?

Currently, there are no approved therapies that effectively address the underlying causes of ENPP1 Deficiency, ABCC6 Deficiency, or calciphylaxis, which underscores the importance of Inozyme Pharma's innovative approach.
Inozyme Pharma, Inc.

Nasdaq:INZY

INZY Rankings

INZY Stock Data

55.45M
63.25M
1.2%
92.62%
6.83%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON